Week of October 11th 2021 | Vol. 10, Issue 41
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Charlotte, NC – Bourne Partners and BPSC, an investment banking and private equity investment business both specialized in the Pharma, Pharma Services, and Consumer Health/OTC sectors is celebrating its 20th anniversary this month. In 2001, Founder and CEO Banks Bourne set out on a mission to change the deal landscape within the healthcare space. The goal was simple, to offer a unique perspective and unmatched experience while remaining highly focused on fulfilling the special needs of established, middle-market healthcare and pharmaceutical companies across the globe. Over the course of the past two decades, that goal has become a reality. As owners and operators with over 20 years of experience, Bourne Partners has strived to enrich the lives and improve the health and well-being of their partners and patients across the globe by facilitating the efficient movement of capital through the global healthcare sector.
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
4 transactions totaling $32 million
Supplies, Equipment & Services
13 transactions totaling $1,937 million
Healthcare IT & Managed Care
5 transactions totaling $2,475 million
Healthcare Facilities & Distributors
6 transactions totaling $3 million
Pharma & Biotech
23 transactions totaling $975 million
Supplies, Equipment & Services
18 transactions totaling $308 million
Healthcare IT & Managed Care
12 transactions totaling $641 million
Healthcare Facilities & Distributors
3 transaction totaling $34 million
Pharma & Biotech
14 transactions totaling $3,023 million
Supplies, Equipment & Services
9 transactions totaling $773 million
Healthcare IT & Managed Care
1 transaction totaling $1 million
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
October 6, 2021 - Fierce Biotech
Boston Scientific aims to energize its cardiac portfolios by putting down $1.75 billion upfront for Baylis Medical to secure its devices designed to reach the far corners of the heart. The Canadian company’s specialty includes minimally invasive platforms that allow surgeons to accurately cross the thin, internal barrier separating the heart’s upper right and left chambers—providing a path for a catheter to treat atrial fibrillation, seal off the stroke-causing left atrial appendage or help fix a malfunctioning mitral valve.

October 7, 2021 - Fierce Biotech
Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics—a biotech that starts life with $500 million, a collaboration with Amgen and a pipeline of eight prospects. Neumora represents a test of the idea that neuroscience is on the cusp of the sort of rapid progress that has transformed oncology in recent years. If Neumora is right, recent advances in genomics and neurobiology have set the stage for more targeted modulation of the underlying biology of specific brain diseases, just as the oncology field has gone from targeting organs to zeroing in on molecularly defined diseases.

October 8, 2021 - Contract Pharma
Samsung Biologics, a contract development and manufacturing organization, and Enzolytics (ENZC), a drug development company committed to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases, have signed a strategic CDMO partnership agreement. Under the terms of the agreement, Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other Monoclonal Antibodies being developed by Enzolytics.

October 8, 2021 - Contract Pharma
Cambrex unveiled plans to expand its manufacturing center of excellence in High Point, NC. The $30 million investment is designed to meet the continually growing demand for small molecule development and manufacturing services. The expansion will add new chemistry laboratories, two new clinical manufacturing suites and include a small-scale commercial manufacturing operation with three work centers and 2,000-liter reactors. This investment will provide Cambrex with the capabilities to handle the latest R&D process research tools and techniques, increase Cambrex’s equipment offerings to support customer’s speed to market goals, and provide a dedicated facility for orphan drugs and niche therapies.
Events Hosted or Attended by Bourne Partners

Dates TBD - Charlotte, NC

October 5, 2021 - Virtual Webinar

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.